SOVREMENNAYA PEDIATRIYA. 2016.1(73): 44-48 

Rational choice of ethiotropic therapy of ENT inflammatory diseases in children 

Lezhenko G., Pashkova O.

Zaporizhzhia State Medical University 

Etiologic structure of ENT inflammatory diseases in 45 children aged 7 to 15 years (16 children with acute exacerbation of chronic tonsillitis, 14 patients with acute bacterial tonsillopharyngitis and 15 children with acute sinusitis) has studied. In the ENT diseases established domination of bacterias of Haemophilus (53.3%) and Streptococcus pyogenes (22.2%). The application of cephalosporin III Cefpodoxime Proxetil has justified as a starting treatment of ENT bacterial diseases in children. It has shown that the use of Cefpodoxime Proxetil in the treatment of ENT bacterial infections in children is highly effective and safe. The results of clinical and laboratory research and bacteriological methods in 95.6% of patients assessed outcome of treatment as good, in 2.2% — satisfactory, in 2.2% — unsatisfactory. No adverse effects or allergic reactions were observed in the study. 

Key words: ENT inflammatory diseases, oral cephalosporin, Cefpodoxime Proxetil, children. 

REFERENCES

1. DiferentsIyovane zastosuvannya antibakterIalnih preparatIv v pedIatrIYi (po materIalah IX VseukraYinskoYi naukovo-praktichnoYi konferentsIYi «AktualnI pitannya pedIatrIYi»). Novosti meditsini I farmatsIYi. 2007. 21—22: 230—231.

2. Karpova EP, Bozhatova MP. 2010. Sovremennyie vozmozhnosti antibakterialnoy terapii u detey s hronicheskimi tonzillitami. RMZh. 1: 8—10.

3. Kosenko IM. 2011. O ratsionalnom ispolzovanii antibiotikov pri infektsiyah LOR-organov. Farmateka. 1: 40—46.

4. Kuchiyants SA, Gappoeva ET, Bolieva LZ. 2014. Differentsirovannyie podhodyi k lecheniyu hronicheskogo tonzillita na osnovanii dannyih kliniko-immunologicheskogo obsledovaniya. Kubanskiy nauch med vestn. 2: 76—79.

5. NovI perspektivi vikoristannya peroralnih tsefalosporinov v pedIatrIYi. Po materIalah V Kongresu pedIatrIv UkraYini, 15—17 zhovtnya, m. KiYiv. Zdorov'ya UkrayinI. 2008. 24/1: 36—37.

6. Berezhnoy VV, Kozachuk VG, Orlyuk IB, Kirnos AI, Azarov IV, Kurilo LV. 2007. The experience of «Cephadox» usage in complex treatment of purulent sinusitis in children. Sovremennaya pediatriya. 3: 88—92.

7. Piskunov GZ, Piskunov SZ. 2012. Klinicheskaya rinologiya. Moskva, Med inform ag: 560.

8. Strachunskiy LS, Kozlov SN. 2002. Sovremennaya antimikrobnaya himioterapiya. Moskva, Borges: 206.

9. Feygina VM. 2002. Profilaktika i lechenie tonzillitov u detey. Lechaschiy vrach. 9: 46-49.

10. Yakovlev SV, Dvoretskiy LI, Suvorova MP. 2002. Bakterialnyie infektsii v ambulatornoy praktike: vyibor optimalnogo antibakterialnogo preparata. Consilium Medicum. 4; 1 (reprint): 8—15.

11. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Sinus and Allergy Health Partnership. Otolaryngol Head Neck Surg. 2000. 123; 1 Pt 2: 5—31. http://dx.doi.org/10.1067/mhn.2000.107873; PMid:10887346

12. Brook I. 2005. Chronic sinusitis in children and adultis: role of bacteria and antimicrobial management. Curr Alleray Astma Rep. 5(6): 482—490. http://dx.doi.org/10.1007/s11882-005-0030-z

13. Hoban D, Felmingham D. 2002. The PROTEKT surveillance study: antimicrobial susceptibility of Haemophilus influenzae and Moraxella catarrhalis from community-acquired respiratory tract infections. J Antimicrob Chemother. Suppl S1: 49—59. http://dx.doi.org/10.1093/jac/dkf810; PMid:12239228

14. Mc Isaac WJ, Goel V, To T, Low DE. 2000. The validity of a sore throat score in family practice. CMAJ. 163; 7: 811—815.

15. Wald ER. 2002. Sinusitis. Pediatric infectious diseases principles and practice. Ed by Jenson HB, Baltimore RS. 1st ed. 1: 760—770.